Increased Trimethylation of Histone H3K36 Associates with Biliary Differentiation and Predicts Poor Prognosis in Resectable Hepatocellular Carcinoma

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2018 Oct 26

PMID 30356299

Citations 10

Authors

Huang-Chun Lien

Yung-Ming Jeng

Yu-Ling Jhuang

Ray-Hwang Yuan

Affiliations

Soon will be listed here.

Abstract

Introduction: Trimethylation of histone H3K36 (H3K36me3), an epigenetic marker of transcription-associated histone modification and stem cell regulation, is expressed in a variety of human cancers. This study elucidated the prognostic significance of H3K36me3 in patients with resectable hepatocellular carcinoma (HCC).

Methods: Expression of H3K36me3 was retrospectively evaluated through immunohistochemistry in 152 surgically resected primary HCCs.

Results: In nontumorous liver parenchyma, H3K36Me3 was detected in bile ducts but not in hepatocytes. H3K36me3 was positive in 104 (68.4%) of the HCCs. Positivity for H3K36me3 was associated with high level of serum α-fetoprotein (>200 ng/mL, P = 0.0148), high tumor grade (P = 0.0017), and high tumor stage (P = 0.0008). Patients with H3K36me3-positive tumors were more likely to have lower 5-year disease-free survival and 5-year overall survival than those with H3K36me3-negative tumors (P = 0.0484 and P = 0.0213, respectively). Multivariate analysis showed that H3K36me3 positivity was an independent predictor of high tumor grade (P = 0.0475) and high tumor stage (P = 0.0114) and thus contributed to poor prognosis. Furthermore, H3K36me3 positivity was significantly correlated with the expression of biliary markers cytokeratin 19 (CK19) and hepatocyte nuclear factor 1β (HNF1β) (P < 0.0001 and P = 0.0005, respectively). Combinatorial analysis revealed that CK19 and HNF1β expression individually exerted additive prognostic adverse effects on HCCs with H3K36me3 positivity.

Conclusions: Our study indicates that H3K36me3 positivity is associated with the expression of biliary markers and is a crucial predictor of poor prognosis in resectable HCC.

Citing Articles

Deficiency of the histone H3K36 methyltransferase SETD2 inhibits the proliferation and migration of hepatocellular carcinoma cells.

Yang Y, Zhang L, Munyurangabo G, Zhou Y, He S, Zhang P J Cancer. 2024; 15(20):6479-6489.

PMID: 39668826 PMC: 11632984. DOI: 10.7150/jca.97844.

Deletion of mdig enhances H3K36me3 and metastatic potential of the triple negative breast cancer cells.

Thakur C, Qiu Y, Zhang Q, Carruthers N, Yu M, Bi Z iScience. 2022; 25(10):105057.

PMID: 36124233 PMC: 9482110. DOI: 10.1016/j.isci.2022.105057.

Tumor-matrix interaction induces phenotypic switching in liver cancer cells.

Yuan R, Hsu C, Jhuang Y, Liu Y, Hsieh T, Jeng Y Hepatol Int. 2022; 16(3):562-576.

PMID: 35525880 DOI: 10.1007/s12072-022-10315-w.

Pterostilbene Changes Epigenetic Marks at Enhancer Regions of Oncogenes in Breast Cancer Cells.

Harandi-Zadeh S, Boycott C, Beetch M, Yang T, Martin B, Ren K Antioxidants (Basel). 2021; 10(8).

PMID: 34439480 PMC: 8388921. DOI: 10.3390/antiox10081232.

Circulating cell-free nucleosomes as biomarker for kidney transplant rejection: a pilot study.

Verhoeven J, Baan C, Peeters A, Clahsen-van Groningen M, Nieboer D, Herzog M Clin Epigenetics. 2021; 13(1):32.

PMID: 33573704 PMC: 7879674. DOI: 10.1186/s13148-020-00969-4.

References

EDMONDSON H, STEINER P . Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954; 7(3):462-503. DOI: 10.1002/1097-0142(195405)7:3<462::aid-cncr2820070308>3.0.co;2-e. View

Li X, Shi B, Yang Q, Wu J, Wu H, Wang Y . Epigenetic regulation of CDH1 exon 8 alternative splicing in gastric cancer. BMC Cancer. 2015; 15:954. PMC: 4682244. DOI: 10.1186/s12885-015-1983-5. View

Yang P, Guo L, Duan Z, Tepper C, Xue L, Chen X . Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop. Mol Cell Biol. 2012; 32(15):3121-31. PMC: 3434505. DOI: 10.1128/MCB.00204-12. View

Yuan R, Jeng Y, Chen H, Lai P, Pan H, Hsieh F . Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol. 2006; 209(4):549-58. DOI: 10.1002/path.2011. View

Hsu H, Huang A, Lai P, Chien W, Peng S, Lin S . Genetic alterations at the splice junction of p53 gene in human hepatocellular carcinoma. Hepatology. 1994; 19(1):122-8. View

Yuan R, Lai H, Hsu H, Lai P, Jeng Y . Expression of bile duct transcription factor HNF1β predicts early tumor recurrence and is a stage-independent prognostic factor in hepatocellular carcinoma. J Gastrointest Surg. 2014; 18(10):1784-94. DOI: 10.1007/s11605-014-2596-z. View

Endo K, Ueda T, Ueyama J, Ohta T, Terada T . Immunoreactive E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients' survival. Hum Pathol. 2000; 31(5):558-65. DOI: 10.1053/hp.2000.6683. View

Lee W, Teckie S, Wiesner T, Ran L, Prieto Granada C, Lin M . PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet. 2014; 46(11):1227-32. PMC: 4249650. DOI: 10.1038/ng.3095. View

Fontebasso A, Schwartzentruber J, Khuong-Quang D, Liu X, Sturm D, Korshunov A . Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathol. 2013; 125(5):659-69. PMC: 3631313. DOI: 10.1007/s00401-013-1095-8. View

10.

Hsu H, Tseng H, Lai P, Lee P, Peng S . Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness. Cancer Res. 1993; 53(19):4691-4. View

11.

Young L, Hendzel M . The oncogenic potential of Jumonji D2 (JMJD2/KDM4) histone demethylase overexpression. Biochem Cell Biol. 2013; 91(6):369-77. DOI: 10.1139/bcb-2012-0054. View

12.

Lewis P, Muller M, Koletsky M, Cordero F, Lin S, Banaszynski L . Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science. 2013; 340(6134):857-61. PMC: 3951439. DOI: 10.1126/science.1232245. View

13.

Yuan R, Jeng Y, Hu R, Lai P, Lee P, Cheng C . Role of p53 and β-catenin mutations in conjunction with CK19 expression on early tumor recurrence and prognosis of hepatocellular carcinoma. J Gastrointest Surg. 2010; 15(2):321-9. DOI: 10.1007/s11605-010-1373-x. View

14.

Lee S, Lee Y, Bae J, Choi J, Tayama C, Hata K . HBx induces hypomethylation of distal intragenic CpG islands required for active expression of developmental regulators. Proc Natl Acad Sci U S A. 2014; 111(26):9555-60. PMC: 4084425. DOI: 10.1073/pnas.1400604111. View

15.

Schafer D, Sorrell M . Hepatocellular carcinoma. Lancet. 1999; 353(9160):1253-7. DOI: 10.1016/S0140-6736(98)09148-X. View

16.

Ho T, Kapur P, Joseph R, Serie D, Eckel-Passow J, Tong P . Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death. Mod Pathol. 2015; 29(1):34-42. PMC: 4697879. DOI: 10.1038/modpathol.2015.123. View

17.

Gan L, Yang Y, Li Q, Feng Y, Liu T, Guo W . Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomark Res. 2018; 6:10. PMC: 5845366. DOI: 10.1186/s40364-018-0122-2. View

18.

Roskams T, De Vos R, Van Eyken P, Myazaki H, Van Damme B, Desmet V . Hepatic OV-6 expression in human liver disease and rat experiments: evidence for hepatic progenitor cells in man. J Hepatol. 1998; 29(3):455-63. DOI: 10.1016/s0168-8278(98)80065-2. View

19.

Befeler A, Di Bisceglie A . Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology. 2002; 122(6):1609-19. DOI: 10.1053/gast.2002.33411. View

20.

Kouzarides T . Chromatin modifications and their function. Cell. 2007; 128(4):693-705. DOI: 10.1016/j.cell.2007.02.005. View